Ivonescimab is a first-in-class, investigational bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor.
A risk prediction model using longitudinal eGFR data could help identify kidney transplant recipients at risk for graft ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, discusses the safety and toxicity management of amivantamab ...
Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR ...
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.
Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and ...
Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results